A recent in-vitro study suggests that BCR-ABL expression enhance TGFβ1 levels and TGFβ signaling activity in CML cell lines33, which prompted us to inquire whether increased serum levels in our cohort are also leading to increased signaling activity. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.